Home Molecular Testing Methods Targeted Variant Test: Known Mutation, Family Testing, and Results

Targeted Variant Test: Known Mutation, Family Testing, and Results

By
Vita Library
-
27
Targeted variant testing checks relatives for a known family mutation. Learn who should test, what positive and true-negative results mean, and how to follow up.

A targeted variant test answers a narrow genetic question: is a specific, already identified DNA change present in this person? It is commonly used after a pathogenic or likely pathogenic variant has been found in a relative. The laboratory examines the exact familial change rather than sequencing an entire gene or searching broadly across the genome. This makes testing faster, less expensive, and less likely to produce unrelated or uncertain findings.

The quality of the answer depends on accurate information about the original variant. The laboratory usually needs the relative’s report, including the gene, transcript, DNA and protein notation, zygosity, and testing laboratory. A “negative” targeted result is a true negative only when the family’s disease-causing variant is well established and the person is biologically at risk of inheriting it. Testing an unverified family story or a variant of uncertain significance can create false reassurance or unnecessary anxiety.

  • Targeted testing checks one known familial variant, not every possible change in the gene.
  • It is often used for cascade testing of relatives, carrier testing, and reproductive planning.
  • A positive result means the specific variant was detected; its medical effect depends on inheritance and penetrance.
  • A true negative can return risk toward the family’s background level for that variant.
  • The original laboratory report should be reviewed before a relative is tested.

Table of Contents

The Question a Targeted Test Answers

Targeted variant testing is sometimes called known familial variant testing, site-specific testing, mutation-specific testing, or single-site analysis. Its scope is deliberately limited. The laboratory does not usually examine the rest of the gene for other pathogenic variants unless a broader test is ordered separately.

The typical sequence is:

  1. An affected or high-risk person—the index case or proband—has diagnostic genetic testing.
  2. A pathogenic or likely pathogenic variant is identified and judged to explain or materially contribute to the condition.
  3. Relatives who could have inherited that variant are offered targeted testing.
  4. Each relative’s result is interpreted according to the condition’s inheritance pattern, age, sex, and clinical history.

This family-based process is known as cascade testing because testing moves outward through successive branches of the family. It can identify relatives who need surveillance or treatment and spare noncarriers from unnecessary condition-specific care.

A targeted assay is different from a single-gene sequencing test. Full-gene sequencing searches many positions within a gene because the exact variant is unknown. Targeted analysis checks only the documented change. It can therefore answer “Did this person inherit the family variant?” but not “Does this person have any genetic cause of the condition?”

The narrow scope is an advantage when used correctly. There is little chance of discovering a second, unrelated condition or a new variant of uncertain significance. Interpretation is usually straightforward because the variant was evaluated in the index case. Turnaround can be shorter, and laboratories may charge less than for comprehensive sequencing.

The narrow scope is a disadvantage when the family diagnosis is incomplete. A relative may test negative for one variant yet carry a different pathogenic variant in the same gene or another gene, especially if that side of the family has additional disease patterns. Targeted testing should not replace an independent diagnostic evaluation in a relative whose symptoms are unexplained by the family variant.

The word “mutation” is still common in test names, but “variant” is preferred because not every DNA change is harmful. The test should be based on a variant classified as pathogenic or likely pathogenic, not merely on the fact that a difference was found.

Who May Benefit From Family-Variant Testing

Eligibility begins with inheritance. A genetics professional maps the family relationship and determines who has a realistic chance of carrying the variant.

First-degree relatives

Parents, siblings, and children are first-degree relatives. For many autosomal dominant conditions, each first-degree relative of a carrier has up to a 50% chance of carrying the same variant. Testing these relatives often provides the greatest immediate benefit.

For an autosomal recessive condition, parents of an affected child are usually carriers, and siblings may be affected, carriers, or noncarriers. Adult relatives may seek carrier testing for reproductive planning. Testing one known variant may be sufficient in relatives of a documented carrier, but partners generally need broader carrier screening because they are unlikely to carry the exact family change unless it is common or there is shared ancestry.

More distant relatives

Aunts, uncles, cousins, nieces, nephews, and grandchildren may also be at risk. The most efficient approach usually tests the relative closest to the known carrier first. If that person is negative, descendants on that branch generally do not need testing for the familial variant because it could not have passed through them. If positive, testing can continue down that branch.

This stepwise strategy reduces unnecessary tests and clarifies which side of the family carries the variant. Exceptions occur when family relationships are uncertain, a parent is unavailable, or mosaicism is suspected.

Symptomatic relatives

A relative with symptoms can have targeted testing, but the clinician should ask whether the familial variant fully explains that person’s presentation. If symptoms differ substantially, broader diagnostic testing may be more appropriate. A negative targeted result in a symptomatic relative does not prove the symptoms are nongenetic.

Healthy adults at future risk

Predictive testing can identify an adult who carries a variant associated with later-onset cancer, cardiac disease, neurologic disease, or another condition. Testing is most useful when the result changes surveillance, prevention, medication, or reproductive planning.

Pretest counseling should address the possibility of a positive result before symptoms develop, variable severity, uncertain age of onset, and insurance or privacy concerns. The decision to test is personal unless immediate medical safety requires urgent clarification.

Children

Testing a child is generally supported when a positive result would change care during childhood—for example, by prompting cardiac monitoring, tumor surveillance, medication precautions, or treatment. Predictive testing for an exclusively adult-onset condition is often deferred so the child can decide as an adult, unless professional guidance identifies a childhood benefit.

A child who is already symptomatic may need diagnostic testing regardless of typical age-of-onset rules. The care team should separate testing for current medical evaluation from testing only to predict distant adult risk.

Prenatal and preimplantation testing

Once a familial variant is known, targeted prenatal diagnosis can be performed on chorionic villus or amniotic fluid DNA. Preimplantation genetic testing may be developed for embryos created through in vitro fertilization. These are specialized services that require advance planning, confirmation of the family variant, and safeguards against sample contamination and allele dropout.

What Must Be Known Before the Test

A verbal description such as “the breast cancer gene” or “a mutation in exon 4” is not enough. Genes have multiple transcripts, and the same variant can be written in different coordinate systems. Testing the wrong site could produce a technically correct but clinically useless result.

The original report should provide:

  • the exact gene symbol;
  • reference transcript and version;
  • genomic coordinates and genome build when available;
  • cDNA notation, such as a change beginning with “c.”;
  • protein notation, such as a change beginning with “p.”;
  • variant type and zygosity;
  • classification and supporting interpretation;
  • method used and the laboratory that issued the report;
  • date of classification.

The receiving laboratory may request a copy rather than accepting transcribed information. It may need to confirm that the variant is within its validated range or obtain a positive control from the index case.

Confirm the variant’s classification

Cascade testing is most appropriate for pathogenic and likely pathogenic variants. A variant of uncertain significance should not usually be used for predictive testing because its relationship to disease is unknown. Finding the VUS in a healthy relative does not necessarily make it benign, and not finding it does not prove the relative is safe.

Occasionally, family studies are ordered to help classify a VUS. This is different from clinical cascade testing. The laboratory or genetics team should specify what segregation pattern would be informative and explain that the result may not resolve uncertainty.

Variant classifications can change. If the original report is old, the index case may need reinterpretation before relatives are tested. A variant once called pathogenic may have been downgraded, or an uncertain variant may now have stronger evidence.

Establish the family relationship

A pedigree identifies who is connected through the side of the family carrying the variant. This prevents testing relatives who are not biologically at risk. Adoption, donor conception, misattributed parentage, and limited family information can complicate the assessment and should be handled sensitively.

Define the clinical purpose

Before testing, the person should know what a positive or negative result would change. Possible goals include cancer screening, cardiac monitoring, ending unnecessary surveillance, reproductive planning, medication decisions, or explaining symptoms. When no management or personal decision would change, some people reasonably choose to postpone testing.

Review consent and privacy

Testing can reveal risk to relatives and may uncover unexpected biological relationships. Consent should address who will receive the result, whether the laboratory retains the sample, and how information may be used. Legal protections against genetic discrimination vary by country and insurance type.

How the Laboratory Detects the Variant

The method is selected to match the known change. “Targeted” describes the scope, not a single technology.

Small sequence variants

Single-nucleotide changes and small insertions or deletions are often tested by PCR followed by Sanger sequencing. The laboratory amplifies a short region around the site and checks whether the reference or altered sequence is present. Allele-specific PCR, real-time PCR, or targeted NGS can also be used.

Sanger sequencing is well suited to many family variants, but it may not reliably detect low-level mosaicism. If the index case has a mosaic variant or a parent is being evaluated for low-level mosaicism, a deep sequencing or digital method may be required.

Exon and whole-gene copy-number variants

A familial deletion or duplication may be tested by multiplex ligation-dependent probe amplification, quantitative PCR, digital PCR, microarray, or targeted read-depth analysis. Sequencing only the breakpoint region works if the exact junction is known and stable in the family.

The test must distinguish the family event from other copy-number changes. A negative single-exon assay does not exclude a different deletion elsewhere in the gene.

Repeat expansions

Known repeat expansions require repeat-primed PCR, fragment analysis, Southern blot, or another validated repeat method. A conventional single-site base assay cannot measure repeat length. The report may classify an allele as normal, intermediate, premutation, reduced penetrance, or full mutation depending on the disorder.

Structural rearrangements

Familial inversions, translocations, and insertions may require karyotype, FISH, breakpoint PCR, genome sequencing, or optical genome mapping. The method should detect the exact balanced or unbalanced structure. A chromosomal microarray alone cannot exclude a balanced familial translocation.

Methylation and mitochondrial variants

An imprinting or methylation defect requires a methylation-sensitive assay. Mitochondrial variants require a method validated for heteroplasmy and the relevant tissue. A person can carry different variant proportions in blood, urine, muscle, or other tissues.

Most inherited family testing uses blood or saliva. A second specimen may be recommended when a positive result will lead to major intervention or when sample identity is uncertain. Prenatal specimens require maternal-cell contamination checks. Tumor findings suspected to be hereditary must be confirmed in a normal tissue because a tumor-only variant may be somatic.

The laboratory should report the analytic sensitivity and limitations of the chosen method. A test designed to detect a heterozygous germline variant may not be adequate for low-level mosaicism or cell-free DNA.

Positive, Negative, and Inconclusive Results

Targeted results are usually simpler than broad sequencing results, but the words “positive” and “negative” still require context.

Positive result

A positive result means the familial variant was detected. The report should state whether the person is heterozygous, homozygous, hemizygous, or mosaic when that can be determined.

For a dominant condition, a heterozygous positive result generally means the person has increased risk or a molecular diagnosis, depending on symptoms and penetrance. For a recessive condition, one familial variant usually indicates carrier status. If the relative is symptomatic or the reproductive partner also carries a variant in the same gene, comprehensive analysis may be needed to look for a second allele.

A positive result does not predict the exact age of onset or severity unless robust variant-specific data exist. Relatives with the same variant can have different outcomes because of modifying genes, environment, sex, age, and chance.

True negative result

A true negative occurs when a person tests negative for a confirmed familial pathogenic variant that they had a defined chance of inheriting. This result usually means they did not inherit the variant and cannot pass that specific variant to children.

For many dominant cancer or cardiac syndromes, a true negative returns the person’s risk related to that familial variant toward population or personal-history levels. It can allow condition-specific surveillance to stop when professional guidance supports doing so. Ordinary screening based on age, sex, symptoms, and unrelated family history still applies.

A true negative does not guarantee that the person will never develop the disease. Sporadic disease and other genetic causes remain possible. It also does not exclude a different condition suggested by personal symptoms.

Uninformative negative result

A negative result is uninformative when there is no confirmed familial pathogenic variant. Testing an unaffected relative with a small panel and finding nothing cannot establish that the family’s disease is not inherited. The best initial testing usually begins with an affected relative who is most likely to carry the cause.

A targeted negative can also be uninformative if the family’s reported variant was not documented, if the relationship to the carrier is uncertain, or if the assay did not match the variant type.

Carrier-negative result

A relative who tests negative for a known recessive family variant is unlikely to carry that specific change. They may still carry another pathogenic variant in the same gene at the background population frequency. Whether broader carrier screening is appropriate depends on ancestry, partner status, and reproductive goals.

Inconclusive or failed result

A test can fail because of insufficient DNA, contamination, poor amplification, complex sequence, or inability to distinguish a gene from a pseudogene. The report may recommend a new sample or another method. An inconclusive result should not be treated as negative.

Unexpected result

Occasionally, the laboratory detects the variant at a lower level than expected, suggesting mosaicism, or finds a genotype inconsistent with the stated relationship. The laboratory may request repeat testing, a second specimen, or parental samples. Sensitive communication is essential because technical explanations must be excluded before conclusions about family relationships are drawn.

Inheritance, Penetrance, and Family Communication

A family variant is shared information, but the laboratory report belongs to the tested person. In most health systems, clinicians cannot directly contact relatives without permission except in rare circumstances defined by law and ethics. The index case is usually encouraged to share a family letter or report copy.

Family communication can be difficult. Relatives may be geographically distant, estranged, young, or unaware of the diagnosis. Medical terminology can be confusing, and some people fear discrimination or emotional harm. A concise letter should explain that a hereditary variant was found, which side of the family may be affected, what test to request, and where to obtain counseling—without pressuring the recipient.

Cascade testing often stops after the first few relatives even though many remain at risk. Programs that provide standardized letters, telehealth counseling, low-cost testing, and patient navigation can improve access. Language, culture, cost, and availability of genetics professionals influence participation.

Penetrance is the proportion of carriers who develop a trait. A variant with incomplete penetrance can be present in a healthy relative. This does not automatically disprove pathogenicity. Age-related penetrance is common: a young carrier may not yet have manifestations.

Variable expressivity means carriers can have different symptoms or severity. One relative may have early cancer, another late disease, and another no diagnosed condition. Medical plans should therefore use variant-specific evidence and each person’s clinical profile.

A positive result can affect emotional well-being. Some people feel relief from ending uncertainty; others experience guilt, anxiety, or altered family relationships. A negative result can also produce survivor guilt when siblings are positive. Genetic counseling provides space to discuss these responses and supports autonomous decisions.

Family testing may reveal that the variant was inherited from a parent previously believed unaffected. That finding can prompt a new medical evaluation and may identify subtle or age-dependent features. It can also redirect which extended relatives are at risk.

Medical, Reproductive, and Practical Next Steps

After a positive result, the next action should come from condition-specific guidance. Possible steps include earlier screening, more frequent imaging, cardiac evaluation, medication precautions, risk-reducing surgery, specialist referral, or symptom awareness. The report itself should not be used as a treatment plan.

For inherited cancer risk, management depends on the gene, variant, organ risk, age, sex, and family history. For inherited cardiac conditions, a carrier may need electrocardiography, imaging, rhythm monitoring, or exercise advice even if asymptomatic. For metabolic or pharmacogenetic conditions, medication and dietary decisions require specialist review.

Reproductive counseling translates the result into pregnancy risk. In a dominant condition, a heterozygous carrier often has a 50% chance of transmitting the variant in each pregnancy. In a recessive condition, risk of an affected child depends on the partner’s status. X-linked, mitochondrial, imprinting, and structural variants follow different rules.

Available reproductive options can include:

  • natural conception without prenatal testing;
  • chorionic villus sampling or amniocentesis for targeted diagnosis;
  • in vitro fertilization with preimplantation genetic testing;
  • donor sperm, eggs, or embryos;
  • adoption;
  • deciding not to have children.

These options differ in timing, cost, accuracy, access, and personal acceptability. Counseling should provide information without directing the family toward one choice.

After a true negative, ask which surveillance can safely return to ordinary recommendations. The clinician should document that the result is negative for the specific familial variant, not “all genetic disease.” Keep a copy of both the index case’s report and the relative’s result because future providers may otherwise misunderstand the context.

After an uninformative negative, identify the best affected relative for comprehensive testing. If that person is unavailable, a genetics professional can judge whether a broader panel is reasonable in the unaffected relative, while explaining that interpretation may remain limited.

After a VUS-based family study, await formal reclassification rather than treating segregation alone as a diagnosis. The testing laboratory should issue or confirm any classification change.

Finally, revisit old family results when new information emerges. Laboratories update nomenclature and classifications, new genes become clinically relevant, and management guidance changes. Targeted testing is most effective when it is anchored to a current, verified family diagnosis and connected to a clear plan for medical care.

References

Disclaimer

This article is for general education and is not a substitute for genetic counseling or medical advice. Eligibility, testing methods, privacy rules, and management recommendations vary by condition and location. Family members should use the original laboratory report and consult qualified professionals before testing or changing care.

RELATED ARTICLESMORE FROM AUTHOR